To tackle historically intractable targets, we have developed a platform employing targeted degradation. Specifically, we have engineered fusion constructs involving two components I) mini-proteins/peptides with high-affinity against therapeutic targets linked to II) truncated E3 ligase receptors. These ‘bioPROTACs’ have proven broadly successful with many constructs showing robust degradation activity. Currently, we aim to apply this technology as research tools and therapeutically by pursuing delivery strategies of bioPROTAC mRNAs.

Harnessing bioPROTACs to achieve rapid and robust protein knockdown

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.